Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Moderna Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss increased by 286.8% to $3.60B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 103.6%, from $1.77B to $3.60B. Over 4 years (FY 2021 to FY 2025), Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss shows a downward trend with a -43.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase suggests recent market headwinds impacting the valuation of the fixed-income portfolio.
Detailed definition
The cumulative amount of unrealized losses for debt securities that have been in a continuous loss position for less tha...
Peer comparison
Standard disclosure for insurance companies to track the aging of unrealized losses.
other_debt_securities_available_for_sale_continuous_unre_d33b47Historical Data
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.35B | $13.00B | $13.64B | $9.87B | $7.64B | $3.41B | $2.40B | $1.76B | $1.37B | $3.67B | $3.45B | $887.00M | $1.67B | $1.77B | $2.00B | $869.00M | $931.00M | $3.60B |
| QoQ Change | — | +39.1% | +4.9% | -27.6% | -22.7% | -55.3% | -29.8% | -26.6% | -22.1% | +168.0% | -5.9% | -74.3% | +88.6% | +5.7% | +12.8% | -56.5% | +7.1% | +286.8% |
| YoY Change | — | — | — | — | -18.3% | -73.7% | -82.4% | -82.2% | -82.1% | +7.5% | +44.2% | -49.5% | +22.2% | -51.8% | -42.2% | -2.0% | -44.4% | +103.6% |
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss at Other Companies
Frequently Asked Questions
- What is Moderna's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss?
- Moderna (MRNA) reported debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss of $3.60B in Q1 2026.
- How has Moderna's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss changed year-over-year?
- Moderna's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss increased by 103.6% year-over-year, from $1.77B to $3.60B.
- What is the long-term trend for Moderna's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss?
- Over 4 years (2021 to 2025), Moderna's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss has grown at a -43.8% compound annual growth rate (CAGR), from $9.35B to $931.00M.
- What does debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss mean?
- The total dollar amount of paper losses on debt securities that have been losing value for less than a year.